- Home
- CEV vs PYXS Comparison
CEV vs PYXS Comparison
Compare CEV & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CEV | PYXS |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.6M | 82.3M |
| IPO Year | 1998 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CEV | PYXS |
|---|---|---|
| Price | $10.30 | $1.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 26.6K | ★ 334.1K |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.03 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,858,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $7,043.98 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.35 | $0.87 |
| 52 Week High | $10.78 | $5.55 |
Technical Indicators
Market Signals| Indicator | CEV | PYXS |
|---|---|---|
| Relative Strength Index (RSI) | 52.85 | 63.21 |
| Support Level | $9.99 | $1.28 |
| Resistance Level | $10.59 | $2.17 |
| Average True Range (ATR) | 0.16 | 0.11 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 92.16 | 90.72 |
Price Performance
Historical ComparisonAbout CEV Eaton Vance California Municipal Income Trust Shares of Beneficial Interest
Eaton Vance CA Muni Income Trust is a non-diversified closed-end investment company. The company's investment objective is to provide current income exempt from regular federal income tax and California state personal income taxes. It invests in municipal obligations, issued by the State of California or its political subdivisions, agencies, authorities and instrumentalities and also has some exposure to corporate bonds.
About PYXS Pyxis Oncology Inc.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.